3Hewitt P R.Antitrust and intellectual property[EB/OL].usdoj.gov/atr/public/speeches/200701.htm,2007-01-16.
4Ebersole J T,Guthrie C M,Goldstein A J.Patent pools and standard setting in diagnostic genetics[EB/OL].nature.com/nbt/journal/v23/n8/full/nbt0805-937.html,2007-01-18.
5Cockburn M I.Blurred boundaries:Tensions between open scientific resources and commercial exploitation of knowledge in biomedical research[EB/OL].people.bu.edu/cockburn/cockburn-blurred-boundaries.pdf,2007-01-16.
6Adelman E D.A fallacy of the commons in biotech patent policy[J].Berkeley Tech L J,2005(20):985-1023.
7Signaure Genomic Libari,LLC and Affymetrix,Inc.Sign license agreement[EB/OL].forbes.com/businesswire/feeds/businesswire/2006/02/14businesswire20060214006128rl.html,2007-01-20.
8Brief for Amicus Curiae Affymetrix,Inc.In Support of Appellee,In re Fisher,421 F.3d 1365 (Fed.Cir.2005) (No.04-1465)[EB/OL].patentlaw.typepad.com/patent/files/affymetrix_amicus_brief.pdf,2007-01-21.
9Personalized Medicine Coalition.Comments on SACGHS Draft Report "Coverage and Reimbursement of Genetic Test and Services"[EB/OL].personalizedmedicinecoalition.org/sciencepolicy/public-policy_sacghs-position.php,2007-01-22.
10Lawrence M Sung,Don J Pelto.Greater predictability may result in patent pools as the federal circuit refines scope of biotech claims[J/OL].ljx.com/patents/0622pools.html,2007-01-26.
